Should I buy or sell Atossa Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATOS shares. View ATOS analyst ratings or view top-rated stocks .

What is Atossa Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 1-year price targets for Atossa Therapeutics' stock. Their ATOS share price targets range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 191.3% from the stock's current price. View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts .

How have ATOS shares performed in 2024?

Atossa Therapeutics' stock was trading at $0.88 at the beginning of 2024. Since then, ATOS shares have increased by 75.6% and is now trading at $1.5450. View the best growth stocks for 2024 here .

When is Atossa Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our ATOS earnings forecast .

How were Atossa Therapeutics' earnings last quarter?

Atossa Therapeutics, Inc. (NASDAQ:ATOS) announced its earnings results on Monday, April, 1st. The company reported ($0.06) earnings per share (EPS) for the quarter.

When did Atossa Therapeutics' stock split?

Atossa Therapeutics shares reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?

8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com . Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.

What other stocks do shareholders of Atossa Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO) , Alibaba Group (BABA) , Heat Biologics (HTBX) , Vaxart (VXRT) , Biocept (BIOC) , MannKind (MNKD) , Biopharmx (BPMX) , Daré Bioscience (DARE) , OPKO Health (OPK) and Nokia Oyj (NOK) .

How do I buy shares of Atossa Therapeutics?

Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ATOS

Atossa Therapeutics (ATOS) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)

Free ATOS Stock Alerts

$1.54

-0.17 (-9.94%)

(As of 04/16/2024 ET)

Compare

Today's Range: $1.53
▼
$1.69
50-Day Range: $0.90
▼
$2.10
52-Week Range: $0.59
▼
$2.31

Volume: 1.71 million shs
Average Volume: 1.36 million shs
Market Capitalization: $192.96 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.50

Get Atossa Therapeutics alerts:

Atossa Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 191.3% Upside
$4.50 Price Target
Short Interest: Bearish
8.43% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.54
Based on 13 Articles This Week
Insider Trading: Acquiring Shares
$44,250 Bought Last Quarter
Proj. Earnings Growth: Decreasing
From ($0.28) to ($0.35) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.36 out of 5 stars

Medical Sector

761st out of 930 stocks

Pharmaceutical Preparations Industry

343rd out of 423 stocks

3.5

Analyst's Opinion

Consensus Rating
Atossa Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Atossa Therapeutics has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
8.43% of the outstanding shares of Atossa Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Atossa Therapeutics has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Atossa Therapeutics has recently increased by 24.53%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Atossa Therapeutics does not currently pay a dividend.
Dividend Growth
Atossa Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ATOS.

3.1

News and Social Media Coverage

News Sentiment
Atossa Therapeutics has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 13 news articles for Atossa Therapeutics this week, compared to 2 articles on an average week.
Search Interest
32 people have searched for ATOS on MarketBeat in the last 30 days. This is an increase of 146% compared to the previous 30 days.
MarketBeat Follows
18 people have added Atossa Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Atossa Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $44,250.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.80% of the stock of Atossa Therapeutics is held by insiders.
Percentage Held by Institutions
Only 12.74% of the stock of Atossa Therapeutics is held by institutions.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Atossa Therapeutics are expected to decrease in the coming year, from ($0.28) to ($0.35) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Atossa Therapeutics is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Atossa Therapeutics is -6.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Atossa Therapeutics has a P/B Ratio of 2.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Gold Safe Exchange

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

Click here now to download the free Precious Metals Buying Guide!

About Atossa Therapeutics Stock (NASDAQ:ATOS)

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

ATOS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ATOS Stock News Headlines

April 13, 2024 | insidertrades.com

Jonathan Finn Buys 25,000 Shares of Atossa Therapeutics, Inc. (NASDAQ:ATOS) Stock

April 16, 2024 | insidermonkey.com

5 Micro-Cap Healthcare Stocks Insiders Are Buying

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.

April 15, 2024 | markets.businessinsider.com

Promising Synergies: Atossa Therapeutics’ Advances in ER+/HER2- Breast Cancer Treatment

April 15, 2024 | proactiveinvestors.com

Atossa Therapeutics announces breast cancer trial evaluating lead asset in combination with Eli Lilly drug

April 15, 2024 | globenewswire.com

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial to Evaluate (Z)-Endoxifen in Combination with Abemaciclib (VERZENIO®) in Women with ER+/HER2- Breast Cancer

April 11, 2024 | globenewswire.com

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

April 10, 2024 | markets.businessinsider.com

Atossa Therapeutics Poised for Growth with Promising Breast Cancer Treatment

April 16, 2024 | Gold Safe Exchange (Ad)

Trump’s “Tax Free” Retirement Strategy

April 10, 2024 | markets.businessinsider.com

Atossa Therapeutics: Strong Buy on Promising EVANGELINE Study Results and Z-endoxifen Efficacy Potential

April 9, 2024 | msn.com

Atossa stock climbs 11% on breast cancer drug data

April 9, 2024 | proactiveinvestors.com

Atossa Therapeutics reports positive data from breast cancer treatment trial

April 9, 2024 | globenewswire.com

Atossa Therapeutics Presents Data from 40mg Cohort of Phase 2 EVANGELINE Clinical Trial Showing 100% Disease Control Rate After 24-Weeks of Treatment with (Z)-Endoxifen

April 3, 2024 | finance.yahoo.com

Atossa Therapeutics Inc (ATOS) Year-End Earnings: A Comprehensive Analysis

April 3, 2024 | finanznachrichten.de

Atossa Therapeutics, Inc.: Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

April 3, 2024 | markets.businessinsider.com

Optimistic Outlook for Atossa Therapeutics’ Z-endoxifen in Breast Density and Cancer Therapy

April 2, 2024 | bizjournals.com

PSBJ taking nominations for CFO of the Year through April 5

April 1, 2024 | msn.com

ATOS Stock Earnings: Atossa Therapeutics Misses EPS for Q4 2023

April 1, 2024 | proactiveinvestors.com

Atossa Therapeutics sets sights on breast cancer trial results after strong quarter of clinical milestones

April 1, 2024 | globenewswire.com

Atossa Therapeutics Announces Year-End 2023 Financial Results and Provides Corporate Update

March 28, 2024 | bizjournals.com

Introducing the Inno Madness Bracket

March 20, 2024 | proactiveinvestors.com

Atossa Therapeutics' breast cancer drug milestone sparks investor enthusiasm

March 19, 2024 | bizjournals.com

Atossa Therapeutics back in Nasdaq's good graces

March 19, 2024 | proactiveinvestors.com

Atossa Therapeutics reports successful five-year treatment outcome for breast cancer patient using (Z)-endoxifen

March 19, 2024 | globenewswire.com

Atossa Therapeutics Provides Five-Year (Z)-Endoxifen Treatment Update on FDA-Approved "Expanded Access" Program for a U.S. Breast Cancer Patient

March 18, 2024 | globenewswire.com

Atossa Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Listing Requirements

March 16, 2024 | finance.yahoo.com

ATOS Apr 2024 4.000 call

See More Headlines

Receive ATOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atossa Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 4/01/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/20/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ATOS
CUSIP: N/A
CIK: 1488039
Web: atossatherapeutics.com
Phone: (206) 588-0256
Fax: 206-430-1288
Employees: 11
Year Founded: 2009

Price Target and Rating

Average Stock Price Target: $4.50
High Stock Price Target: $5.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +179.5%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.24)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-30,090,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -31.01%
Return on Assets: -29.77%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 17.61
Quick Ratio: 17.61

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.73 per share
Price / Book: 2.21

Miscellaneous

Outstanding Shares: 125,300,000
Free Float: 115,530,000
Market Cap: $201.73 million
Optionable: Optionable
Beta: 1.19

Social Links

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

Dr. Steven C. Quay FCAP (Age 73)
M.D., Ph.D., Chairman, CEO & President
Comp: $1.14M
Ms. Heather Rees (Age 52)
SVP, Finance & Principal Accounting Officer
Ms. Delly Behen P.H.R.
Senior Vice President of Administration & HR
Mr. Eric Van Zanten
Vice President of Investor & Public Relations
Dr. Richard Graydon M.D.
Ph.D., Interim Chief Medical Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ATOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Atossa Therapeutics stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Atossa Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ATOS shares.
View ATOS analyst ratings or view top-rated stocks.
What is Atossa Therapeutics' stock price target for 2024?: 2 Wall Street research analysts have issued 1-year price targets for Atossa Therapeutics' stock. Their ATOS share price targets range from $4.00 to $5.00. On average, they predict the company's stock price to reach $4.50 in the next twelve months. This suggests a possible upside of 191.3% from the stock's current price.
View analysts price targets for ATOS or view top-rated stocks among Wall Street analysts.
How have ATOS shares performed in 2024?: Atossa Therapeutics' stock was trading at $0.88 at the beginning of 2024. Since then, ATOS shares have increased by 75.6% and is now trading at $1.5450.
View the best growth stocks for 2024 here.
When is Atossa Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024.
View our ATOS earnings forecast.
How were Atossa Therapeutics' earnings last quarter?: Atossa Therapeutics, Inc. (NASDAQ:ATOS) announced its earnings results on Monday, April, 1st. The company reported ($0.06) earnings per share (EPS) for the quarter.

When did Atossa Therapeutics' stock split?: Atossa Therapeutics shares reverse split on Friday, April 20th 2018. The 1-12 reverse split was announced on Friday, April 20th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, April 19th 2018. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.
What is Steven C. Quay's approval rating as Atossa Therapeutics' CEO?: 8 employees have rated Atossa Therapeutics Chief Executive Officer Steven C. Quay on Glassdoor.com. Steven C. Quay has an approval rating of 53% among the company's employees. This puts Steven C. Quay in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies. 29.0% of employees surveyed would recommend working at Atossa Therapeutics to a friend.
What other stocks do shareholders of Atossa Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Atossa Therapeutics investors own include AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Heat Biologics (HTBX), Vaxart (VXRT), Biocept (BIOC), MannKind (MNKD), Biopharmx (BPMX), Daré Bioscience (DARE), OPKO Health (OPK) and Nokia Oyj (NOK).
How do I buy shares of Atossa Therapeutics?: Shares of ATOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ATOS) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial